Skip to Main Content

Paper Details

Response to: "Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication".
J Am Acad Dermatol
0
2022
Author NameAffiliation
Jonathan W RickUniversity of Arkansas for Medical Sciences
  • 1 - 1

Datasets

Release 1.2